📊 SGRY Key Takeaways
Is Surgery Partners, Inc. (SGRY) a Good Investment?
Surgery Partners demonstrates solid operational fundamentals with 6.2% revenue growth and $389.5M operating income, but is burdened by excessive leverage (2.18x debt/equity) that converts operating profitability into net losses of $77.9M. High debt service costs relative to free cash flow of $195.6M create sustainability concerns despite positive operating cash flow.
Why Buy Surgery Partners, Inc. Stock? SGRY Key Strengths
- Revenue growth of 6.2% YoY demonstrates market demand and operational scale in healthcare services
- Positive operating income of $389.5M with 11.8% operating margin shows core business viability
- Strong free cash flow of $195.6M supports debt service and provides operational flexibility
SGRY Stock Risks: Surgery Partners, Inc. Investment Risks
- High leverage ratio of 2.18x debt/equity with substantial long-term debt of $3.7B limits financial flexibility and refinancing risk
- Net loss of $77.9M and negative net margin of -2.4% despite positive operations indicates debt burden is unsustainable relative to earnings capacity
- Negative ROE (-4.5%) and ROA (-1.0%) indicate poor capital efficiency and shareholder value destruction
Key Metrics to Watch
- Debt service coverage ratio and interest expense trends relative to operating cash flow
- Path to net income profitability and net margin expansion
- Debt reduction progress and leverage ratio trend toward healthier levels
Surgery Partners, Inc. (SGRY) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Surgery Partners, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
SGRY Profit Margin, ROE & Profitability Analysis
SGRY vs Healthcare Sector: How Surgery Partners, Inc. Compares
How Surgery Partners, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Surgery Partners, Inc. Stock Overvalued? SGRY Valuation Analysis 2026
Based on fundamental analysis, Surgery Partners, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Surgery Partners, Inc. Balance Sheet: SGRY Debt, Cash & Liquidity
SGRY Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Surgery Partners, Inc.'s revenue has grown significantly by 49% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.09 indicates the company is currently unprofitable.
SGRY Revenue Growth, EPS Growth & YoY Performance
SGRY Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $770.4M | -$22.7M | $-0.18 |
| Q2 2025 | $762.1M | -$2.5M | $-0.02 |
| Q1 2025 | $717.4M | -$12.4M | $-0.10 |
| Q3 2024 | $674.1M | -$4.9M | $-0.04 |
| Q2 2024 | $667.6M | -$6.0M | $-0.05 |
| Q1 2024 | $666.2M | -$12.4M | $-0.10 |
| Q3 2023 | $620.6M | -$4.9M | $-0.04 |
| Q2 2023 | $615.4M | -$6.0M | $-0.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Surgery Partners, Inc. Dividends, Buybacks & Capital Allocation
SGRY SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Surgery Partners, Inc. (CIK: 0001638833)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 16, 2026 | 4 | xslF345X05/wk-form4_1773691658.xml | View → |
| Mar 16, 2026 | 4 | xslF345X05/wk-form4_1773691652.xml | View → |
| Mar 16, 2026 | 4 | xslF345X05/wk-form4_1773691647.xml | View → |
| Mar 16, 2026 | 4 | xslF345X05/wk-form4_1773691640.xml | View → |
| Mar 16, 2026 | 4 | xslF345X05/wk-form4_1773691632.xml | View → |
❓ Frequently Asked Questions about SGRY
What is the AI rating for SGRY?
Surgery Partners, Inc. (SGRY) has an AI rating of HOLD with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SGRY's key strengths?
Claude: Revenue growth of 6.2% YoY demonstrates market demand and operational scale in healthcare services. Positive operating income of $389.5M with 11.8% operating margin shows core business viability.
What are the risks of investing in SGRY?
Claude: High leverage ratio of 2.18x debt/equity with substantial long-term debt of $3.7B limits financial flexibility and refinancing risk. Net loss of $77.9M and negative net margin of -2.4% despite positive operations indicates debt burden is unsustainable relative to earnings capacity.
What is SGRY's revenue and growth?
Surgery Partners, Inc. reported revenue of $3.3B.
Does SGRY pay dividends?
Surgery Partners, Inc. does not currently pay dividends.
Where can I find SGRY SEC filings?
Official SEC filings for Surgery Partners, Inc. (CIK: 0001638833) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SGRY's EPS?
Surgery Partners, Inc. has a diluted EPS of $-0.61.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SGRY a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Surgery Partners, Inc. has a HOLD rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SGRY stock overvalued or undervalued?
Valuation metrics for SGRY: ROE of -4.5% (sector avg: 15%), net margin of -2.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SGRY stock in 2026?
Our dual AI analysis gives Surgery Partners, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SGRY's free cash flow?
Surgery Partners, Inc.'s operating cash flow is $274.3M, with capital expenditures of $78.7M. FCF margin is 5.9%.
How does SGRY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2.4% (avg: 12%), ROE -4.5% (avg: 15%), current ratio 1.87 (avg: 2).
Is Surgery Partners, Inc. carrying too much debt?
SGRY has a debt-to-equity ratio of 2.18x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.87 suggests adequate short-term liquidity.